Comparison of the Immunogenicity and Safety of Two Pediatric TBE Vaccines Based on the Far Eastern and European Virus Subtypes

Table 5

Relationship between immunogenicity and reactogenicity of the TBE vaccines.

Schedule	Subjects	Number of subjects	Immunogenicity (after 2 doses)
			14 days	30 days
Conventional	With reactions	23	nd	95.7/2.2 (1.1–3.3)
	With no reactions	68	nd	98.5/2.6 (1.0–3.3)
Rapid	With reactions	12	66.7/2.3^a (1.3–3.3)	100/2.8 (1.6–3.3)
	With no reactions	43	53.5/1.5^a (1.0–3.3)	97.7/2.8 (1.1–3.3)

Numerator, SRs; denominator, GMTA. ( ), nAbs titer range; nd, not determined. ^aDifference in nAbs titers (MWT).